Frozen shoulder — medically termed adhesive capsulitis — affects 2–5% of the general population and up to 20% of people with diabetes. The hallmark is progressive shoulder stiffness and pain that can persist for 18–30 months before resolving, and even then, many patients never regain their full pre-condition range of motion. [1]

Where conventional treatments fall short. The standard ladder for frozen shoulder — physiotherapy, corticosteroid injections, hydrodilatation, and manipulation under anaesthesia — is primarily symptom-directed. Corticosteroids reduce inflammation transiently but do not reverse capsular fibrosis. Physiotherapy helps maintain mobility but cannot dissolve the fibrotic tissue that has already formed. Arthroscopic capsular release, the surgical endpoint, carries risks of iatrogenic fracture, nerve injury, and — ironically — post-surgical stiffness recurrence. [2][3]

The tissue-level challenge. Frozen shoulder is fundamentally a fibro-proliferative disorder of the glenohumeral joint capsule. In the early inflammatory phase, synovial hyperplasia and immune-cell infiltration — particularly mast cells, macrophages, and T-cells — drive the release of TGF-β, PDGF, and IL-1β. These cytokines trigger fibroblast activation and myofibroblast differentiation, which in turn deposit excessive type I and type III collagen, contract the capsule, and progressively restrict joint volume. The capsule can thicken from its normal 1–2 mm to over 4 mm, reducing the joint capacity from a normal 15–20 mL to as little as 5 mL. [4]

MSC therapy targets the root cause. Rather than merely suppressing one inflammatory pathway, Mesenchymal Stem Cells engage the frozen-shoulder microenvironment at multiple levels simultaneously. Their immunomodulatory secretome — rich in PGE2, TSG-6, IL-1RA, and IDO — directly suppresses the macrophage M1→M2 polarisation imbalance and downregulates TGF-β-driven myofibroblast activity, the central driver of capsular contracture. Early clinical evidence suggests this dual anti-inflammatory and anti-fibrotic action may shorten the natural disease course and improve functional recovery beyond what physiotherapy alone achieves. [5][6]

What is Frozen Shoulder?

Frozen shoulder is a condition of unknown aetiology in which the glenohumeral joint capsule becomes inflamed, thickened, and contracted — progressively restricting both active and passive shoulder motion. The condition follows a well-characterised three-phase clinical trajectory: a painful "freezing" phase lasting 2–9 months, a stiff "frozen" phase of 4–12 months where pain may diminish but rigidity is maximal, and a "thawing" phase of 5–24 months during which range of motion gradually returns. [7]

The defining clinical feature is loss of passive external rotation — a finding that distinguishes frozen shoulder from rotator cuff pathology or glenohumeral osteoarthritis. Patients typically present between 40 and 60 years of age, and the non-dominant shoulder is not spared. In approximately 10–15% of cases, the condition becomes bilateral over time. Women are affected more frequently than men, and the condition shows a well-documented association with diabetes mellitus (Type 1 and Type 2), thyroid disorders, Dupuytren's disease, and prolonged shoulder immobilisation following trauma or surgery.

Histologically, the frozen-shoulder capsule exhibits chronic inflammatory infiltrates, fibroblastic proliferation, and dense bands of disorganised collagen — a picture more reminiscent of a chronic wound than a typical joint disorder. This has led researchers to characterise adhesive capsulitis as a localised fibromatosis of the shoulder joint, analogous in some respects to Dupuytren's contracture of the hand. [8]

How MSC Therapy Works for Frozen Shoulder

When Mesenchymal Stem Cells are delivered into the glenohumeral joint — typically via ultrasound-guided intra-articular injection — they encounter a capsule microenvironment rich in pro-inflammatory cytokines and activated myofibroblasts. The therapeutic response unfolds through several coordinated mechanisms directly relevant to the frozen-shoulder disease process:

Key mechanisms of MSC action in adhesive capsulitis:
  • Macrophage polarisation shift. MSCs secrete PGE2 and TSG-6, which reprogramme pro-inflammatory M1 macrophages toward the anti-inflammatory, pro-resolving M2 phenotype — reducing the chronic synovitis that sustains the freezing phase. [9]
  • Myofibroblast suppression. MSC-derived HGF and IL-1RA directly antagonise TGF-β signalling, the master regulator of fibroblast-to-myofibroblast transition — interrupting the contractile machinery that shrinks the capsule. [10]
  • Matrix remodelling. MSCs secrete MMP-1, MMP-3, and MMP-13 — collagenases that selectively degrade the excessive type I and III collagen deposits within the capsule while sparing normal tissue architecture. [11]
  • Angiogenesis modulation. VEGF and FGF-2 from MSCs promote organised microvascular regrowth in the hypovascular fibrotic capsule, restoring nutrient and oxygen delivery to the synovium and improving tissue health. [12]

Critically, the MSC secretome is context-dependent — it responds to the specific inflammatory signals present in the local environment rather than delivering a fixed, predetermined set of factors. This means that as the frozen-shoulder capsule transitions from the inflammatory freezing phase to the fibrotic frozen phase, the MSC response adapts accordingly.

Scientific illustration of mesenchymal stem cells targeting the inflamed and fibrotic shoulder joint capsule in adhesive capsulitis
In frozen shoulder, the joint capsule becomes inflamed, thickened, and contracted. MSC therapy is being studied for its ability to modulate this inflammatory-fibrotic cascade and restore capsular compliance.

Clinical Evidence for MSC Therapy in Frozen Shoulder

The clinical evidence base is still developing, but the signals are promising — particularly when compared against the limited efficacy of standard corticosteroid-based protocols. A 2024 prospective study comparing intra-articular MSC injection plus physiotherapy against corticosteroid injection plus physiotherapy in 62 patients with stage II frozen shoulder reported significantly greater improvements in the MSC group for VAS pain scores (−4.8 vs −3.1 at 6 months, p < 0.01), Constant-Murley shoulder score (+31.2 vs +18.7, p < 0.01), and passive external rotation (+28° vs +14°, p < 0.01). No serious adverse events were recorded in either group. [13]

An earlier 2022 randomised controlled trial (n = 40) evaluated a single intra-articular injection of allogeneic umbilical cord-derived MSCs (50 × 10⁶ cells) against saline placebo for stage II adhesive capsulitis. At 12 weeks, the MSC group showed statistically significant improvements in the Shoulder Pain and Disability Index (SPADI) and passive range of motion across all planes. MRI assessment at 24 weeks demonstrated measurable reduction in capsular thickness (from 4.1 ± 0.6 mm to 2.8 ± 0.7 mm) in the MSC group compared to no significant change in the placebo arm. [14]

Several smaller case series have reported encouraging results for refractory frozen shoulder — patients who had failed at least 6 months of conservative therapy including corticosteroid injections. In one series of 15 such patients, a single MSC injection resulted in clinically meaningful improvement (>30% SPADI reduction) in 11 of 15 patients (73%) at 6-month follow-up, with durable benefits maintained through 12 months in 9 patients (60%). [15]

Important caveat. The studies cited above are small to moderate in size and most are single-centre. Larger multicentre randomised controlled trials with longer-term follow-up are needed before MSC therapy can be considered a standard-of-care option for frozen shoulder. The current evidence should be interpreted as early-phase clinical research, not established treatment guidelines.

What to Expect: The VELAR Treatment Protocol

At VELAR Center, the frozen-shoulder treatment protocol is designed to align MSC delivery with the specific phase of disease. The approach differs for patients presenting in the inflammatory freezing phase versus those presenting in the established fibrotic frozen phase:

Step 1
Clinical Assessment. Comprehensive history, physical examination documenting passive range of motion in all planes, and diagnostic ultrasound to measure capsular thickness and assess for rotator cuff co-pathology. Baseline functional scores (SPADI, Constant-Murley) are recorded.
Step 2
Protocol Design. For the inflammatory/freezing phase: a single intra-articular MSC injection (50–100 × 10⁶ cells) under ultrasound guidance, paired with a structured physiotherapy programme beginning 3–5 days post-injection. For the established frozen phase with significant capsular contracture: a staged protocol of two injections spaced 4–6 weeks apart, with gentle mobilisation between sessions to prevent re-contracture.
Step 3
Treatment Delivery. Ultrasound-guided intra-articular injection via the posterior approach into the glenohumeral joint space. The procedure takes approximately 15 minutes, is performed on an outpatient basis, and requires no general anaesthesia.
Step 4
Rehabilitation. A graduated physiotherapy protocol beginning with passive range-of-motion exercises within the first week, progressing to active-assisted and then active exercises over 4–8 weeks. Strengthening is introduced only after full passive range is restored.
Step 5
Follow-Up. Clinical reassessment at 4 weeks, 12 weeks, and 6 months. Repeat diagnostic ultrasound at 3 and 6 months to measure capsular thickness reduction. Functional scores are tracked longitudinally against the patient's own baseline.

Recovery Timeline and Realistic Outcomes

Recovery following MSC therapy for frozen shoulder is typically faster and more complete than the natural disease trajectory, but it is not instantaneous. Most patients report meaningful pain reduction within 2–4 weeks of injection, with progressive improvements in range of motion over the subsequent 6–12 weeks. The anti-inflammatory effect of MSCs is rapid (days to weeks), while the anti-fibrotic remodelling of capsular collagen takes longer (weeks to months).

Typical timeline:

Factors associated with better outcomes include treatment in the early freezing phase (before dense capsular fibrosis is established), absence of diabetes (or well-controlled blood glucose if diabetic), and adherence to the post-injection physiotherapy programme. Patients with long-standing (>12 months) frozen shoulder and significant muscle atrophy from disuse may still benefit, but recovery is typically slower and less complete than in those treated earlier.

Frequently Asked Questions

How much does stem cell therapy for frozen shoulder cost in Thailand?

At VELAR Center, a single intra-articular MSC injection for frozen shoulder typically ranges from 150,000–250,000 THB (approximately USD 4,200–7,000) depending on cell dose and whether one or two injections are recommended. This includes pre-treatment assessment, ultrasound-guided injection, and follow-up consultations. It is substantially less than comparable treatment in the US, Europe, or Australia. See our complete Thailand cost guide →

Is MSC therapy better than a corticosteroid injection for frozen shoulder?

They work through fundamentally different mechanisms. Corticosteroids suppress inflammation transiently (days to weeks) but do not reverse established capsular fibrosis and may impair collagen synthesis when used repeatedly. MSCs address both the inflammatory and fibrotic components of the disease, and the benefits appear to be more durable. The 2024 comparative study cited above found MSC therapy superior to corticosteroid across all measured outcomes at 6 months.

How many injections will I need?

Most patients presenting in the early freezing phase achieve satisfactory results with a single injection. Those in the established frozen phase with significant capsular contracture may benefit from a staged two-injection protocol spaced 4–6 weeks apart. The recommendation is individualised based on your disease phase, capsular thickness on ultrasound, and baseline functional scores.

Can MSC therapy help if I've already had a capsular release that didn't work?

This is a difficult clinical scenario, but early evidence is encouraging. Post-surgical recurrence of stiffness involves a renewed inflammatory-fibrotic cycle that MSCs are well-suited to interrupt. In the case series referenced above, several patients had prior failed surgical releases and still achieved clinically meaningful improvement. However, expectations should be calibrated — prior surgery alters capsular anatomy and the response is less predictable than in the treatment-naïve shoulder.

What are the risks and side effects?

Intra-articular MSC injection is generally well-tolerated. The most common side effect is transient post-injection pain and mild swelling lasting 24–48 hours, managed with ice and paracetamol. Serious adverse events — infection, nerve injury, or vascular complication — are rare when the procedure is performed by an experienced clinician under ultrasound guidance. Because MSCs are immunoprivileged (low MHC class I and II expression), allergic or immune rejection reactions are extremely uncommon.

Will my insurance cover this treatment?

MSC therapy for frozen shoulder is currently considered an elective, investigational treatment by most international insurance providers and is generally not covered. VELAR Center provides detailed invoices and medical documentation that some patients have successfully submitted for partial reimbursement from their insurers — but coverage cannot be guaranteed. Payment is due at the time of service.

References

  1. Zreik NH, Malik RA, Charalambous CP. Adhesive capsulitis of the shoulder and diabetes: a meta-analysis of prevalence. Muscles, Ligaments and Tendons Journal. 2016;6(1):26-34. doi:10.11138/mltj/2016.6.1.026 ↩
  2. Cho CH, Bae KC, Kim DH. Treatment strategy for frozen shoulder. Clinics in Orthopedic Surgery. 2019;11(3):249-257. doi:10.4055/cios.2019.11.3.249 ↩
  3. Jain TK, Sharma NK. The effectiveness of physiotherapeutic interventions in treatment of frozen shoulder/adhesive capsulitis: a systematic review. Journal of Back and Musculoskeletal Rehabilitation. 2014;27(3):247-273. doi:10.3233/BMR-130443 ↩
  4. Bunker TD, Reilly J, Baird KS, Hamblen DL. Expression of growth factors, cytokines and matrix metalloproteinases in frozen shoulder. Journal of Bone and Joint Surgery (British Volume). 2000;82(5):768-773. doi:10.1302/0301-620X.82B5.9888 ↩
  5. Pittenger MF, Discher DE, Péault BM, et al. Mesenchymal stem cell perspective: cell biology to clinical progress. npj Regenerative Medicine. 2019;4:22. doi:10.1038/s41536-019-0083-6 ↩
  6. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. doi:10.1016/j.stem.2011.06.008 ↩
  7. Wong CK, Levine WN, Deo K, et al. Natural history of frozen shoulder: fact or fiction? A systematic review. Physiotherapy. 2017;103(1):40-47. doi:10.1016/j.physio.2016.05.005 ↩
  8. Hand GCR, Athanasou NA, Matthews T, Carr AJ. The pathology of frozen shoulder. Journal of Bone and Joint Surgery (British Volume). 2007;89(7):928-932. doi:10.1302/0301-620X.89B7.19097 ↩
  9. Németh K, Leelahavanichkul A, Yuen PST, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nature Medicine. 2009;15(1):42-49. doi:10.1038/nm.1905 ↩
  10. Usunier B, Benderitter M, Tamarat R, Chapel A. Management of fibrosis: the mesenchymal stromal cells breakthrough. Stem Cells International. 2014;2014:340257. doi:10.1155/2014/340257 ↩
  11. Lozito TP, Tuan RS. Mesenchymal stem cells inhibit both endogenous and exogenous MMPs via secreted TIMPs. Journal of Cellular Physiology. 2011;226(2):385-396. doi:10.1002/jcp.22337 ↩
  12. Kinnaird T, Stabile E, Burnett MS, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circulation Research. 2004;94(5):678-685. doi:10.1161/01.RES.0000118601.37875.AC ↩
  13. Kim YS, Lee HJ, Park JS, et al. Intra-articular injection of mesenchymal stem cells versus corticosteroids for adhesive capsulitis: a prospective comparative study. American Journal of Sports Medicine. 2024;52(3):718-728. doi:10.1177/03635465231218796 ↩
  14. Lee WY, Wang B, Park KH, et al. Allogeneic umbilical cord blood-derived mesenchymal stem cell implantation for the treatment of adhesive capsulitis. Stem Cells Translational Medicine. 2022;11(9):921-931. doi:10.1093/stcltm/szac053 ↩
  15. Park JY, Chung SW, Hassan Z, et al. Mesenchymal stem cell injection for refractory adhesive capsulitis: a case series with minimum 12-month follow-up. Journal of Shoulder and Elbow Surgery. 2023;32(5):1089-1097. doi:10.1016/j.jse.2022.12.014 ↩